Luulyo 28, 2026, dunidu waxay u kuurgashayMaalinta Caalamiga ah ee Cagaarshowga, hindise caalami ah oo loogu talagalay kor u qaadista wacyiga iyo dardargelinta waxqabadka ka dhanka ah cudurka cagaarshowga ee fayraska. Mawduuca sanadkan,"Cagaarshowga: Aan kala saarno,"waxay ku baaqeysaa in meesha laga saaro caqabadaha xaddidaya helitaanka ka hortagga, baaritaanka, daaweynta, iyo daryeelka cudurka beerka.

Iyadoo wax ka yar shan sano ay ka harsan tahay in la gaaro yoolka WHO ee ah in laga takhaluso cudurka cagaarshowga oo ah khatar caafimaad dadweyne marka la gaaro 2030, ballaarinta helitaanka baaritaanka waqtiga ku habboon oo sax ah weligeed ma noqon mid aad muhiim u ah.

Khatarta Aamusnaanta: Culayska Caalamiga ah ee Cagaarshowga Fayraska

Cagaarshowga fayraska waxaa loola jeedaa bararka beerka oo ay keenaan fayrasyada hepatitis, oo ay ku jiraanCagaarshowga A (HAV), B (HBV), C (HCV), D (HDV), iyo E (HEV).

Fayrasyadan dhexdooda,Hepatitis B iyo Hepatitis C oo daba-dheeraada ayaa weli ah sababaha ugu waaweyn ee beerka cirrhosis iyo kansarka beerka ee hepatocellular, badanaa si aamusnaan ah ayay u socotaa sannado ka hor inta aysan calaamaduhu soo muuqan.

Sida laga soo xigtay qiyaasaha WHO, boqolaal milyan oo qof oo adduunka oo dhan ah ayaa la nool caabuqa daba-dheeraada ee HBV ama HCV, halka tiro badan oo dad ah aan weli la ogaan. Cudurka cagaarshowga fayrasku wuxuu sii wadaa inuu sanad walba sababo in ka badan hal milyan oo dhimasho ah, taasoo ugu badan ay sabab u tahay dhibaatooyinka sida cirrhosis iyo kansarka beerka.

Iyadoo ay jiraan xeelado ka hortag iyo daaweyn oo wax ku ool ah, haddana farqiga u dhexeeya ogaanshaha iyo daryeelka ayaa weli ah caqabado waaweyn. Dad badan oo qaba cudurka cagaarshowga daba-dheeraada ayaan ka warqabin infekshankooda sidaas darteedna waxay seegaan fursadaha lagu faragelin karo waqtigeeda.

Baaritaanka: Tallaabada Koowaad ee Loo Qaadayo Ciribtirka Cagaarshowga

Si loo gaaro yoolalka ciribtirka 2030 - oo ay ku jiraan90% hoos u dhac ku yimaada caabuqyada cusub ee hepatitis-ka iyo 65% hoos u dhaca dhimashada la xiriirta hepatitis-ka- ballaarinta daboolida baaritaanka waa lama huraan.

WHO waxay ku nuuxnuuxsanaysaa in hagaajinta helitaanka ogaanshaha waqtiga ku habboon iyo daryeelka dadka ku saleysan ay ka hortagi karto malaayiin dhimasho ah. Si kastaba ha ahaatee, helitaanka baaritaanka la isku halleyn karo oo xaddidan ayaa weli ah mid ka mid ah caqabadaha ugu muhiimsan ee ka hortagaya shakhsiyaadka cudurka qaba inay helaan daaweyn iyo dabagal ku habboon.

Sida bixiye cusubxalalka ogaanshaha ee in vitro, Tijaabada Yar iyo kuwa Macrowaxay ka go'an tahay inay taageerto dadaallada caalamiga ah ee ciribtirka cudurka cagaarshowga iyada oo loo marayo faylal baaritaan oo dhammaystiran oo daboolaya:

• · Baaritaan degdeg ah oo lagu ogaanayo baaxadda weyn 
• · Tijaabada aashitada Nukliyeerka si loo helo ogaanshaha hore iyo saxda ah 
• · La socodka culeyska fayraska ee maaraynta daaweynta 
• · Genotyping-ka loogu talagalay go'aan qaadashada caafimaad ee shaqsiga ah 

Iyada oo la taageerayo xaalado baaritaan oo kala duwan, Macro & Micro-Test waxay gacan ka geysataa ballaarinta helitaanka ogaanshaha cudurka cagaarshowga ee lagu kalsoonaan karo adduunka oo dhan.

Faylalka Baaritaanka Cagaarshowga ee Macro & Micro-Test

1. Baaritaan Degdeg ah: Soo Dhaweynta Baaritaanka Cagaarshowga ee Bulshooyinka

Qalabka Tijaabada Degdegga ah ee Dahabka ColloidalBixi xal fudud, degdeg ah, oo aan qalab lahayn, iyadoo natiijooyin lagu keenayo daqiiqado gudahood. Tijaabooyinkani waxay ku habboon yihiin:

• · Barnaamijyada baaritaanka baaxadda weyn
• · Goobaha daryeelka caafimaadka aasaasiga ah
• · Imtixaan ku salaysan bulshada
• · Deegaanno xaddidan oo kheyraad ah

• Bisad. Maya.	Magaca Badeecada	Nooca Muunadda	Bandhigga
  HWTS-HP011	Qalabka Ogaanshaha Degdegga ah ee HBsAg (Dahabka Colloidal)	Serum, plasma, dhiig dhan	Xasaasiyadda: 99.53%; Gaar ahaanshaha: 99.67%; OPA: 99.63%
  HWTS-HP017	Qalabka Tijaabada Degdegga ah ee Isku-dhafan ee HBsAg iyo HCV Ab (Dahabka Colloidal)	Serum, plasma, dhiig dhan	HBsAg: Sens. 99.7%, Spec. 99.8%, OPA 99.8%; HCV Ab: Sens. 99.7%, Spec. 99.6%, OPA 99.7%
  HWTS-HP013	Qalabka Tijaabada HCV Ab (Dahabka Colloidal)	Dhiig dhan, seeram, balaasma	Xasaasiyadda: 99.39%; Gaar ahaanshaha: 99.81%; OPA: 99.71%

• Xalalkan waxaa ka mid ah,HWTS-HP017 waxay suurtogal ka dhigaysaa in si isku mar ah loo ogaado unugyada difaaca jirka ee HBsAg iyo HCV hal tijaabo., hagaajinta hufnaanta baaritaanka iyo taageeridda istaraatiijiyadaha baaritaanka cagaarshowga ee isku dhafan.
  

  2. Tijaabada Aashitada Nukliyeerka: Ogaanshaha Caabuqa iyadoo la Saxayo

  Tijaabada aashitada nukliyeer-ka ee ku salaysan fluorescence PCRwaxay bixisaa xasaasiyad sare iyo gaar ahaansho iyadoo leh daaqado gaagaaban oo lagu ogaan karo caabuqyada fayraska, taasoo suurtogalinaysa aqoonsashada hore ee caabuqyada fayraska iyo taageeridda go'aan qaadashada caafimaad.

• Bisad. Maya.	Magaca Badeecada	Nooca Muunadda	Bandhigga
  HWTS-HP005A	Qalabka Ogaanshaha Aashitada Nucleic ee Fayraska Hepatitis A (Fluorescence PCR)	Serum/saxaro	LoD: 500 nuqul/mL
  HWTS-HP001	Qalabka Ogaanshaha Aashitada Nucleic ee Fayraska Hepatitis B (Fluorescence PCR)	Serum	LoD: 50 IU/mL
  HWTS-HP003	Qalabka Ogaanshaha Aashitada Nucleic-ga ee Fayraska Hepatitis C (PCR-ga Fluorescence)	Balaasma/serum	50 IU/mL ~ 2×10⁹ IU/mL
  HWTS-HP006A	Qalabka Ogaanshaha Aashitada Nucleic-ga ee Fayraska Hepatitis E (Fluorescence PCR)	Serum/saxaro	LoD: 500 nuqul/mL

• 3. Tirinta iyo Tirakoobka Fayraska ee Culayska Fayraska: Taageerida Maareynta Saxda ah

  Dadka qaba hepatitis B iyo C ee daba-dheeraada,La socodka culeyska fayraska iyo hidde-sidaha ayaa door muhiim ah ka ciyaara maaraynta cudurrada iyo qiimeynta daaweynta.

   

  Bisad. Maya.	Magaca Badeecada	Nooca Muunadda	Bandhigga
  HWTS-HP015	Qalabka Baaritaanka Tirakoobka Daawaynta Fayraska Hepatitis B (DNA) (Fluorescence PCR)	Serum/plasma	Kala duwanaanshaha tirada: 20 IU/mL ~ 2×10⁹ IU/mL
  HWTS-HP002	Qalabka Ogaanshaha Hidde-sidaha Fayraska Hepatitis B (Fluorescence PCR)	Serum/plasma	LoD: 1×10² IU/mL
  HWTS-HP004	Qalabka Ogaanshaha Hidde-sidayaasha HCV (Fluorescence PCR)	Serum/plasma	LoD: 200 IU/mL

• HBV wuxuu ka kooban yahay noocyo badan oo hidde-sideyaal ah (A-I), kuwaas oo saameyn ku yeelan kara astaamaha fayraska iyo maaraynta kiliinikada.HWTS-HP002 iyo HWTS-HP004 waxay bixiyaan macluumaad ku saabsan hidde-sidaha si loo taageero xeeladaha daaweynta ee xog ogaalsan, halkaHWTS-HP015 waxay bixisaa tiro ballaaran oo cabbir ah si loola socdo dhaqdhaqaaqa fayraska inta lagu jiro safarka daaweynta. 
  

  Awoodsiinta Mustaqbalka Ka Baxsan Cagaarshowga Iyada oo Loo Marayo Baaritaanno Sax ah

  Hepatitis-ka fayraska ayaa ahlaga hortagi karo, la maareyn karo, iyo - haddii ay dhacdo hepatitis C - la daweyn karo.

  • · Cagaarshowga Bsi wax ku ool ah ayaa looga hortagi karaa tallaalka waxaana lagu xakameyn karaa maaraynta ku habboon ee fayraska.
  • · Hepatitis Cwaxaa lagu daaweyn karaa daawayn fayras oo toos ah, iyadoo la gaarayo heerarka bogsashada oo ka sarreeya 95%.

  Si kastaba ha ahaatee, tallaabada ugu horreysa had iyo jeer waa isku mid:aqoonso caabuqyada goor hore iyada oo loo marayo baaritaan lagu kalsoonaan karo.

Laga bilaabo baaritaanka degdega ah ilaa ogaanshaha unugyada, laga bilaabo ogaanshaha tayada ilaa la socodka culeyska fayraska iyo hidde-sidaha,Macro & Micro-Test waxay bixisaa faylal dhammaystiran oo baaritaanka hepatitis ah oo daboolaya hepatitis A, B, C, iyo E - oo gacan ka geysanaya jebinta caqabadaha ogaanshaha iyo taageeridda dadaallada caalamiga ah ee ku aaddan ciribtirka hepatitis.

Maalinta Caalamiga ah ee Cudurka Cagaarshowga 2026, aan si wadajir ah uga shaqeyno sidii aan u horumarin lahayn"jabiso" - jabinta caqabadaha, ballaarinta marin u helidda, iyo dardargelinta horumarka mustaqbal aan lahayn cagaarshow.